Shanghai Biomedical Industrial Equity Investment Fund
VC Fund
Huangpu, China
Shanghai Biomedical Industrial Equity Investment Fund is a VC fund in Huangpu focused on Health Care and Medical. Shanghai Biomedical Industrial Equity focuses on areas that are in line with the development strategy of the biomedical industry.
- Total investments:
- 68
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Shanghai Biomedical Industrial Equity Investment Fund invests in
Stages Shanghai Biomedical Industrial Equity Investment Fund invests in
Countries Shanghai Biomedical Industrial Equity Investment Fund invests in
Round sizes
Round size
- Seed
- $8M–$50M
- Series A
- $14M–$43M
- Series B
- $10M–$159M
Investment Focus
Industry
- Health Care 27 (40%)
- Medical 24 (35%)
- Biotechnology 22 (32%)
- Pharmaceutical 17 (25%)
- Biopharma 9 (13%)
Stage
- Series A 16 (24%)
- Seed 12 (18%)
- Series B 9 (13%)
- Series C 7 (10%)
- Venture - Series Unknown 6 (9%)
Country
- China 39 (57%)
- United States 5 (7%)
- Hong Kong 2 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Beyond Therapeutics
|
Beyond Therapeutics employs its ExCEED technology to speed the discovery and development of novel medications for unmet therapeutic needs. | $29.6M / Series A / Jul 30, 2026 | |
BioGeometry
|
BioGeo is an innovative digital startup that specializes in using generative AI in protein creation. BioGeo is dedicated to producing programmable proteins from scratch and utilizing them in synthetic biology and biomedicine by employing artificial intelligence-driven techniques to create links between protein sequence, structure, and function. | Seed / Jun 09, 2026 | |
Beixcell
|
Beixcell develops off-the-shelf cell therapies for patients with many degenerative diseases through universal iPSCs-derived cell products. | Series A / May 06, 2026 | |
Artec Bio
|
Artec Bio is an innovative biotechnology company that specializes in the development of next-generation protein degradation drugs, leveraging cutting-edge research and technology to target and eliminate disease-causing proteins. | Series A / Feb 02, 2026 | |
NeuShen Therapeutics
|
NeuShen Therapeutics is a biotechnology company trailblazing the future treatment of neurological and psychiatric disorders. | Series A / Jan 28, 2026 | |
Fortitude Biomedicines
|
Fortitude Biomedicines is a biotechnology company that develops antibody-based biologic drugs targeting autoimmune diseases. | $13M / Seed / Jan 26, 2026 | |
|
Baiyi Pharmaceutical
|
Baiyi Pharmaceutical is a research-driven pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for neurological diseases, aiming to address unmet medical needs and improve patient outcomes. | $14.3M / Seed / Jan 13, 2026 | |
Haimai Medical
|
Haimai Medical is a platform for tissue engineering and regenerative medicine technology. It focused on the development and manufacture of allogeneic small-caliber tissue-engineered blood vessels suitable for the establishment of chronic renal failure dialysis vascular access, lower extremity arterial trauma blood vessel replacement, lowerextremity atherosclerosis, and coronary heart disease bypass surgery. | $14.3M / Series A / Dec 29, 2025 | |
|
Anhui Qiarui Biotechnology
|
Anhui Qiarui Biotechnology provides Class III blood purification consumables. | Seed / Nov 03, 2025 | |
|
Artec Bio
|
Artec Bio is an innovative biotechnology company that specializes in the development of next-generation protein degradation drugs, leveraging cutting-edge research and technology to target and eliminate disease-causing proteins. | Series A / Aug 01, 2025 | |
| See all 68 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Shanghai Biomedical Industrial Equity Investment Fund invest in?
Shanghai Biomedical Industrial Equity Investment Fund invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Seed stage. Most of the 68 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Shanghai Biomedical Industrial Equity Investment Fund's check size?
Shanghai Biomedical Industrial Equity Investment Fund typically joins rounds of $8M–$50M at Seed, $14M–$43M at Series A and $10M–$159M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Shanghai Biomedical Industrial Equity Investment Fund participates in.
When did Shanghai Biomedical Industrial Equity Investment Fund last invest?
The most recent investment recorded for Shanghai Biomedical Industrial Equity Investment Fund closed in Jul 2026. Shizune tracks 68 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
